Hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) recipients are often at high risk of developing Epstein-Barr virus (EBV)-associated lymphoproliferative disease (PTLD) due to underlying severe immunodeficiency. 1, 2 In particular, impairment of antiviral T-cell immunity as a result of immunosuppressive therapy is a critical risk factor for the development of PTLD. 3 The impact of interaction between EBV with host B-cell subpopulations on the emergence of PTLD in transplant recipients has been a major area of interest for immunobiology experts. Understanding of these interactions may provide clues on how to control EBV-associated PTLD in transplant recipients. Early studies conducted by David Thorley-Lawson and colleagues first demonstrated that EBV persists in resting memory B cells in a nonpathogenic state with limited viral gene expression, which allows these cells to escape from antiviral T-cell control.
4,5 Occasionally, these virus-infected memory B cells differentiate into plasma cells resulting in the activation of the EBV replicative cycle, which allows infection of more naïve B cells. In this issue of Blood, Burns et al have now extended these observations to provide an interesting insight into the biology of EBV infection in HSCT recipients, especially in the context of reconstitution of innate and adaptive immune cells. 
Idelalisib has CLL on the run! -----------------------------------------------------------------------------------------------------Jennifer R. Brown DANA-FARBER CANCER INSTITUTE
In this issue of Blood, O'Brien et al report mature results of initial treatment of chronic lymphocytic leukemia (CLL) with the PI3Kd inhibitor idelalisib plus rituximab, and demonstrate that the combination is extremely effective with manageable toxicity in an older patient population.
1
I n the last several years, a revolution has occurred in the therapy of relapsed CLL. The approvals by the Food and Drug Administration of the Bruton's tyrosine kinase inhibitor ibrutinib for relapsed CLL patients and those with 17p deletion, as well as the approval of idelalisib with rituximab for relapsed CLL patients in whom rituximab is appropriate therapy, have led to the rapid adoption of these targeted therapies as the agents of choice for relapsed CLL. The effectiveness of these drugs, particularly in patients with high-risk cytogenetic abnormalities like 17p deletion, has naturally led to interest in their use for initial therapy, particularly in older patients in whom chemoimmunotherapy is less well-tolerated. Yet upfront data have been quite limited.
In this article, O'Brien et al present the first clinical trial of idelalisib with rituximab for the initial therapy of CLL in patients with a median age of 71 years, 42% of whom had advanced-stage disease. The overall response rate is 97%, with 19% being complete responders, none of whom have progressed to date. The progression-free survival (PFS) is an impressive 83% at 36 months, with only 4 events of disease progression, despite only 23 of 64 patients currently continuing on idelalisib (see figure) . Among the highest-risk TP53-mutated patients (n 5 9), the overall response rate is 100% and none have progressed, consistent with the known excellent activity of idelalisib in relapsed patients in this highrisk group.
2 Although this was a phase 2 study, these results compare very favorably with the current standard of care for this patient population-obinutuzumab chlorambucil-which has a median PFS of 29.2 months in a phase 3 study, 3 and are similar to the smaller phase 1b/2 study of ibrutinib, which showed a PFS of 96% at 30 months, 4 with only 2 TP53-mutated patients. These results certainly justify registration trials of idelalisib in this upfront setting.
Toxicity was not insubstantial, however, with adverse events being the primary reason for discontinuation, occurring in 42% of patients. Grade 3 or higher diarrhea/colitis was seen in 42% of patients, compared with 14% in a recent summary of toxicity in 8 relapsed studies of idelalisib 5 and 6% in the phase 1 study in very heavily pretreated patients. Grade 3 or greater transaminitis was seen in 23% of patients, compared with 14% in the early-relapse studies 5 and 2% in the phase 1 study. Two cases of (fatal) pneumonitis and 2 cases of (reversible) pulmonary fibrosis were also observed. This unique pattern of toxicity with idelalisib, namely colitis, hepatitis, and pneumonitis, is consistent across studies and is seen here to be paradoxically higher in untreated patients. This paradox could be resolved by an immunologic mechanism that might be more intact in less heavily treated patients. In this trial, these toxicities were primarily managed by holding drug, which is essential; but in addition, it has become increasingly clear that corticosteroids are a very effective treatment.
6 Two recent studies characterizing the pathology of idelalisib-induced colitis have found CD8
1 T-cell infiltrates associated with crypt apoptosis as a common feature. 7, 8 Interestingly, the target of idelalisib, namely the d isoform of the PI3K p110 catalytic subunit, is known to be critical for the survival and function of regulatory T cells, 9 and genetic mutations that disrupt regulatory T-cell function in mice and humans lead to a very similar autoimmune syndrome of hepatitis, enteritis, and pneumonitis. 10 In a mouse model of inflammatory bowel disease, adoptive transfer of wild-type T-regulatory cells, but not regulatory T cells deficient in PI3Kd, abolishes autoimmune colitis.
9
Taken together, these findings suggest that idelalisib toxicities may be a result of on-target inhibition of p110 d in regulatory T cells. Correlative studies in ongoing clinical trials will be needed to test this hypothesis in patients. Meanwhile, a high index of suspicion for autoimmune toxicity in patients on idelalisib, with early drug hold and consideration of corticosteroids once infection is ruled out or treated,
